{"id":842345,"date":"2026-10-19T16:39:03","date_gmt":"2026-10-19T16:39:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=842345"},"modified":"2026-10-19T16:39:03","modified_gmt":"2026-10-19T16:39:03","slug":"neuroendocrine-carcinoma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neuroendocrine-carcinoma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight_842345.html","title":{"rendered":"Neuroendocrine Carcinoma Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1792439087.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Neuroendocrine Carcinoma Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1792439087.jpg\" alt=\"Neuroendocrine Carcinoma Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight\" width=\"225\" height=\"95\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Key Neuroendocrine Carcinoma Companies in the market include \u2013 Amgen, Chugai Pharmaceutical, AstraZeneca, Pharma Mar, Jazz Pharmaceuticals, Nippon Kayaku, Daiichi Sankyo, Merck, Zai Lab Limited, GSK, Pfizer, Boehringer Ingelheim, and others.<\/div>\n<p style=\"text-align: justify;\">(Albany, US), October 19, 2026 &#8211; DelveInsight&#8217;s &#8216;Neuroendocrine Carcinoma (NEC) Market Insights, Epidemiology and Market Forecast &ndash; 2036&#8217; report delivers an in-depth understanding of Pulmonary NEC (SCLC) and extrapulmonary NEC (excluding NEPC), historical and forecasted epidemiology, as well as the Neuroendocrine Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\">Explore the intricate details of the Neuroendocrine Carcinoma Market Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-carcinoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Neuroendocrine Carcinoma Treatment Market Size<\/a><\/p>\n<p style=\"text-align: justify;\">Key Takeaways from the Neuroendocrine Carcinoma Market Report<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>In October 2026, Boehringer Ingelheim announced result of A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas.<\/p>\n<\/li>\n<li>\n<p>In September 2026, Latin American Cooperative Oncology Group announced result of Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America.<\/p>\n<\/li>\n<li>\n<p>In 2025, Japan was estimated to account for more than USD 90 million of the Pulmonary NEC (SCLC) market and around USD 8 million of the extrapulmonary NEC (excluding NEPC) market, driven by the increasing adoption of innovative therapies.<\/p>\n<\/li>\n<li>\n<p>A significant proportion of the NEC burden is observed in elderly individuals and males, with most patients presenting with extensive-stage disease at diagnosis, highlighting the need for earlier detection, broader access to effective immunotherapies and targeted therapies, and innovative treatment strategies.<\/p>\n<\/li>\n<li>\n<p>SCLC has witnessed the highest therapeutic progress among NECs, with a strong clinical pipeline and multiple recent approvals.<\/p>\n<\/li>\n<li>\n<p>The treatment paradigm has evolved from chemotherapy to chemo-immunotherapy and now to targeted therapies, improving outcomes in both limited- and extensive-stage disease.<\/p>\n<\/li>\n<li>\n<p>Compared with Pulmonary NEC (SCLC), extrapulmonary NEC (excluding NEPC) remains highly underserved and under-researched, with limited epidemiological data and no dedicated registry to estimate the true disease burden.<\/p>\n<\/li>\n<li>\n<p>In Japan, 2,474 incident cases of EP-NEC (excluding NEPC) were recorded in 2025, and the number is expected to grow to 2,752 by 2036, reflecting increasing recognition of EP-NEC.<\/p>\n<\/li>\n<li>\n<p>The approval of tarlatamab has established DLL3 as the first clinically validated therapeutic target in SCLC. By 2036, the DLL3 class is expected to dominate the NEC Japan market, mainly through DLL3 bispecific antibodies.<\/p>\n<\/li>\n<li>\n<p>A high prevalence of actionable biomarkers in SCLC, including DLL3 (~80%), B7-H3 (~70%), and SLFN11 (~50%), supports the growing shift toward biomarker-driven treatment strategies and targeted patient segmentation.<\/p>\n<\/li>\n<li>\n<p>The leading Neuroendocrine Carcinoma Companies include Amgen, Chugai Pharmaceutical, AstraZeneca, Pharma Mar, Jazz Pharmaceuticals, Nippon Kayaku, Daiichi Sankyo, Merck, Zai Lab Limited, GSK, Pfizer, Boehringer Ingelheim, and others.<\/p>\n<\/li>\n<li>\n<p>Promising Neuroendocrine Carcinoma Therapies include Ifinatamab Deruxtecan (I-DXd), Zocilurtatug pelitecan (ZL-1310), Risvutatug rezetecan (GSK5764227), PF-08634404, Obrixtamig, Pumitamig, ABBV-706, BL-M14D1, Sacituzumab Govitecan, Serplulimab, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Get a Free sample for the Neuroendocrine Carcinoma Market Forecast, Size &amp; Share Analysis Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-carcinoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Neuroendocrine Carcinoma Therapeutics Market<\/a><\/p>\n<p style=\"text-align: justify;\">Neuroendocrine Carcinoma Overview<\/p>\n<p style=\"text-align: justify;\">Neuroendocrine Carcinoma (NEC) is a rare, aggressive malignancy that arises from neuroendocrine cells found throughout the body, most commonly in the lungs, gastrointestinal tract, and pancreas. It is characterized by rapid growth, a high propensity for early metastasis, and poor differentiation in most cases. Symptoms vary depending on the primary tumor site but may include abdominal pain, weight loss, fatigue, cough, or bowel disturbances, while advanced disease can lead to organ dysfunction. NEC is driven by complex genetic and molecular alterations, although the exact causes remain unclear. Pulmonary NEC primarily includes SCLC and large-cell neuroendocrine carcinoma (LCNEC), with SCLC being the most common subtype and accounting for approximately 15% of all lung cancers. EP-NEC refers to high-grade NECs that arise outside the lungs, excluding neuroendocrine prostate cancer (NEPC). Diagnosis is based on clinical presentation, imaging studies, histopathological examination, immunohistochemical markers such as synaptophysin, chromogranin A, and INSM1, and assessment of tumor proliferation using the Ki-67 index. For Pulmonary NEC\/SCLC, staging relies on contrast-enhanced CT, PET-CT, and brain MRI, while molecular biomarker testing for DLL3, SLFN11, and B7-H3 may be performed to identify patients eligible for targeted therapies and clinical trials.<\/p>\n<p style=\"text-align: justify;\">Neuroendocrine Carcinoma Epidemiology Segmentation in the 7MM<\/p>\n<p style=\"text-align: justify;\">Pulmonary NEC\/SCLC<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Incident Cases of Lung Cancer<\/p>\n<\/li>\n<li>\n<p>Total Incident Cases of Pulmonary NEC\/SCLC<\/p>\n<\/li>\n<li>\n<p>Gender-specific Cases of Pulmonary NEC\/SCLC<\/p>\n<\/li>\n<li>\n<p>Age-specific Cases of Pulmonary NEC\/SCLC<\/p>\n<\/li>\n<li>\n<p>Stage-specific Cases of Pulmonary NEC\/SCLC<\/p>\n<\/li>\n<li>\n<p>Biomarker-specific Cases of Pulmonary NEC\/SCLC<\/p>\n<\/li>\n<li>\n<p>Total Treated Cases of Pulmonary NEC\/SCLC by Lines of Therapies<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Extrapulmonary NEC (excluding NEPC)<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Incident Cases of NENs<\/p>\n<\/li>\n<li>\n<p>Total Incident Cases of Extrapulmonary NEC (excluding NEPC)<\/p>\n<\/li>\n<li>\n<p>Stage-specific Cases of Extrapulmonary NEC (excluding NEPC)<\/p>\n<\/li>\n<li>\n<p>Site-specific Cases of Extrapulmonary NEC (excluding NEPC)<\/p>\n<\/li>\n<li>\n<p>Gender-specific Cases of Extrapulmonary NEC (excluding NEPC)<\/p>\n<\/li>\n<li>\n<p>DLL3 Expression Cases of Extrapulmonary NEC (excluding NEPC)<\/p>\n<\/li>\n<li>\n<p>Total Treated Cases of Extrapulmonary NEC (excluding NEPC) by Lines of Therapies<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Download the report to understand which factors are driving Neuroendocrine Carcinoma Epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-carcinoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Neuroendocrine Carcinoma Prevalence<\/a><\/p>\n<p style=\"text-align: justify;\">Neuroendocrine Carcinoma Epidemiology Key Findings<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The incidence of SCLC across the 7MM is expected to increase throughout the study period (2022&ndash;2036), driven by the aging population, continued tobacco exposure in high-risk groups, and improved diagnostic and disease reporting practices.<\/p>\n<\/li>\n<li>\n<p>Among the 7MM, the United States accounted for the highest number of incident NEC cases in 2025 compared with the EU4 &amp; UK and Japan, and this burden is expected to increase over the forecast period.<\/p>\n<\/li>\n<li>\n<p>In 2025, incident cases of NEC were substantially higher among males than females in the United States, and the majority of incident cases occurred in individuals aged &ge;65 years.<\/p>\n<\/li>\n<li>\n<p>In Japan in 2025, DLL3-positive NEC represented the largest share of biomarker-specific cases with 14,935 cases, followed by B7-H3-positive NEC (~13,000 cases) and SLFN11-positive NEC (~9,000 cases).<\/p>\n<\/li>\n<li>\n<p>The incidence of EP-NEC across the 7MM is expected to increase through 2036, driven by improved diagnostic capabilities, increasing disease awareness, greater use of advanced imaging and immunohistochemical testing, and an aging population.<\/p>\n<\/li>\n<li>\n<p>In the United States, gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) accounted for the largest proportion of site-specific EP-NEC cases in 2025, while genitourinary neuroendocrine carcinoma represented the smallest share.<\/p>\n<\/li>\n<li>\n<p>In Japan in 2025, the majority of treated EP-NEC cases received first-line therapy, while substantially fewer patients progressed to second-line and third-line or later treatments, reflecting the aggressive nature of the disease and limited effective options after frontline therapy.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Approved Therapies for Neuroendocrine Carcinoma<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Tarlatamab-dlle (IMDELLTRA): Amgen<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Tarlatamab-dlle is an IV infusion, first-in-class, DLL3-targeting BiTE immunotherapy designed to redirect T cells to selectively recognize and eliminate DLL3-expressing NEC cells while minimizing damage to normal tissues. By simultaneously binding DLL3 on tumor cells and CD3 on T cells, it promotes T-cell activation, cytokine release, and targeted tumor cell killing. Following its approval for previously treated ES-SCLC, Amgen is expanding its DeLLphi program across multiple settings, including first-line induction and maintenance therapy, second-line treatment, and limited-stage disease following chemoradiotherapy.<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Atezolizumab (TECENTRIQ): Chugai Pharmaceutical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Atezolizumab is a PD-L1&ndash;targeting immune checkpoint inhibitor designed to restore antitumor immune responses by blocking the interaction of PD-L1 with the PD-1 and B7.1 receptors on T cells. In SCLC, TECENTRIQ is approved in combination with platinum-based chemotherapy as a first-line treatment for ES-NEC, with ongoing clinical research exploring optimized combination strategies.<\/p>\n<p style=\"text-align: justify;\">Neuroendocrine Carcinoma Pipeline Analysis<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Ifinatamab Deruxtecan (I-DXd): Daiichi Sankyo and Merck<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Ifinatamab Deruxtecan is a B7-H3-directed ADC comprising a humanized anti-B7-H3 monoclonal antibody linked to a deruxtecan (DXd) topoisomerase I inhibitor payload via a cleavable tetrapeptide-based linker. Upon binding to B7-H3, the ADC is internalized, releasing the cytotoxic payload intracellularly to induce DNA damage and tumor cell death while also enabling a bystander antitumor effect. The drug is being evaluated in Phase III, II, and I\/II studies in ES-SCLC, where early clinical data have shown encouraging and durable antitumor activity with a manageable safety profile.<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Zocilurtatug pelitecan (ZL-1310): Zai Lab<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Zocilurtatug pelitecan is a DLL3-targeted ADC comprising a humanized anti-DLL3 monoclonal antibody linked to a novel camptothecin-derived topoisomerase I inhibitor payload, built on the proprietary TMALIN ADC platform. Based on its encouraging systemic and intracranial activity and favorable safety profile, it has the potential to become a best-in-class DLL3-targeted therapy. The company plans to initiate three registration-enabling studies across second-\/third-line NEC and first-line SCLC by the end of 2026. The drug is currently in Phase III.<\/p>\n<p style=\"text-align: justify;\">Discover more about therapies set to grab Major Neuroendocrine Carcinoma Market Share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-carcinoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Neuroendocrine Carcinoma Market Drivers and Barriers<\/a><\/p>\n<p style=\"text-align: justify;\">Neuroendocrine Carcinoma Market Outlook<\/p>\n<p style=\"text-align: justify;\">The Pulmonary NEC\/SCLC market is undergoing a significant transformation, driven by the integration of immunotherapies, targeted therapies, and biomarker-directed treatment approaches. For decades, platinum-based chemotherapy remained the cornerstone of treatment; however, immune checkpoint inhibitors and DLL3-targeted therapies have begun to reshape the paradigm across both LS-SCLC and ES-SCLC. Recent approvals, including durvalumab (IMFINZI) in LS-SCLC and tarlatamab (IMDELLTRA) in relapsed ES-SCLC, have expanded options and addressed longstanding unmet needs, while a robust pipeline of bispecific antibodies, ADCs, and novel immunotherapy combinations is expected to further improve outcomes. The EP-NEC (excluding NEPC) market is evolving as increasing recognition of this rare and aggressive malignancy, improved diagnostics, and expanding clinical research drive demand for more effective treatments. Management remains largely dependent on platinum-based chemotherapy, with no approved therapies specifically indicated for epNEC, while emerging DLL3-targeted agents, ADCs, and bispecific T-cell engagers show promise in relapsed or refractory disease. The United States accounted for the largest share of both the Pulmonary NEC\/SCLC and EP-NEC markets during the study period, while Europe and Japan continue to strengthen their treatment landscape through regulatory approvals, improved access to immunotherapies, and growing clinical trial participation.<\/p>\n<p style=\"text-align: justify;\">Neuroendocrine Carcinoma Treatment Landscape<\/p>\n<p style=\"text-align: justify;\">The primary goals of NEC treatment are to prolong survival, delay disease progression, and improve quality of life. For Pulmonary NEC\/SCLC, management includes platinum-based chemotherapy (etoposide\/irinotecan + cisplatin\/carboplatin) combined with immune checkpoint inhibitors such as IMFINZI (durvalumab) and TECENTRIQ (atezolizumab) for first-line therapy, with ZEPZELCA (lurbinectedin) and IMDELLTRA (tarlatamab) used for maintenance or relapsed disease. For EP-NEC (excluding NEPC), management relies on platinum-based chemotherapy, with immune checkpoint inhibitors and lurbinectedin used in selected settings. Key factors driving the market include rising NEC incidence, particularly among males, and growing opportunities in therapeutic development, including DLL3-targeted therapies, ADCs, bispecific T-cell engagers, and novel immunotherapies. Key unmet needs include high relapse rates despite first-line immunotherapy, no established standard of care beyond second-line therapy, delayed and complex diagnosis in EP-NEC, and a scarcity of targeted therapies.<\/p>\n<p style=\"text-align: justify;\">To know more about Neuroendocrine Carcinoma Companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-carcinoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Neuroendocrine Carcinoma Market Access and Reimbursement<\/a><\/p>\n<p style=\"text-align: justify;\">Scope of the Neuroendocrine Carcinoma Market Report<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Coverage- 7MM<\/p>\n<\/li>\n<li>\n<p>Study Period- 2022-2036<\/p>\n<\/li>\n<li>\n<p>Forecast Period- 2026-2036<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine Carcinoma Companies- Amgen, Chugai Pharmaceutical, AstraZeneca, Pharma Mar, Jazz Pharmaceuticals, Nippon Kayaku, Daiichi Sankyo, Merck, Zai Lab Limited, GSK, Pfizer, Boehringer Ingelheim, and others.<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine Carcinoma Therapies- Tarlatamab-dlle (IMDELLTRA), Atezolizumab (TECENTRIQ), Durvalumab (IMFINZI), Lurbinectedin (ZEPZELCA), Amrubicin (CALSED), Ifinatamab Deruxtecan (I-DXd), Zocilurtatug pelitecan (ZL-1310), Obrixtamig, Gocatamig (MK-6070), Peluntamig (PT217), and others.<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine Carcinoma Market Dynamics: Neuroendocrine Carcinoma market drivers and market barriers<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine Carcinoma Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine Carcinoma Unmet Needs, KOL Views, Reimbursement<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Table of Contents<\/p>\n<ol style=\"text-align: justify;\">\n<li>\n<p>Key Insights<\/p>\n<\/li>\n<li>\n<p>Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Market Forecast Methodology<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine Carcinoma (NEC) Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Disease Background and Overview of Neuroendocrine Carcinoma (NEC)<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population of Neuroendocrine Carcinoma (NEC)<\/p>\n<\/li>\n<li>\n<p>Patient Journey of Neuroendocrine Carcinoma (NEC)<\/p>\n<\/li>\n<li>\n<p>Marketed Therapies<\/p>\n<\/li>\n<li>\n<p>Emerging Drugs<\/p>\n<\/li>\n<li>\n<p>Neuroendocrine Carcinoma (NEC): 7MM Analysis<\/p>\n<\/li>\n<li>\n<p>Unmet Needs of Neuroendocrine Carcinoma (NEC)<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis of Neuroendocrine Carcinoma (NEC)<\/p>\n<\/li>\n<li>\n<p>KOL Views of Neuroendocrine Carcinoma (NEC)<\/p>\n<\/li>\n<li>\n<p>Market Access and Reimbursement of Neuroendocrine Carcinoma (NEC)<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ol>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Abhishek kumar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=neuroendocrine-carcinoma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=neuroendocrine-carcinoma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Neuroendocrine Carcinoma Companies in the market include \u2013 Amgen, Chugai Pharmaceutical, AstraZeneca, Pharma Mar, Jazz Pharmaceuticals, Nippon Kayaku, Daiichi Sankyo, Merck, Zai Lab Limited, GSK, Pfizer, Boehringer Ingelheim, and others. (Albany, US), October 19, 2026 &#8211; DelveInsight&#8217;s &#8216;Neuroendocrine &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/neuroendocrine-carcinoma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight_842345.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,410,417,412],"tags":[],"class_list":["post-842345","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Manufacturing-Industry","category-Marketing-Sales","category-News-Current-Affairs"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/842345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=842345"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/842345\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=842345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=842345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=842345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}